What the AMC tests in substance use
Substance use questions appear across the exam, not only in psychiatry. A confused man on a surgical ward on day two, a young woman with recurrent vomiting, a new mother who drinks, and a patient asking for a benzodiazepine script are all substance use questions in disguise.
The exam tests three broad skills. First, acute medical management: alcohol withdrawal, Wernicke encephalopathy, opioid overdose, and stimulant toxicity. Second, longer-term treatment: relapse prevention medicines for alcohol, opioid agonist treatment, and safe tapering of benzodiazepines. Third, primary care skills: screening, brief intervention and motivational interviewing.
Stems are usually framed as 'most appropriate next step' or 'most appropriate initial management'. The answers reward safe sequencing: thiamine before glucose, a withdrawal scale before treatment decisions, and waiting for objective opioid withdrawal before the first buprenorphine dose.
- Alcohol use disorder, withdrawal, Wernicke and Korsakoff
- Opioid use disorder, overdose and opioid agonist treatment
- Methamphetamine intoxication, psychosis and withdrawal
- Cannabis harms and cannabinoid hyperemesis syndrome
- Benzodiazepine dependence and tapering
- Gambling disorder and brief intervention
Alcohol: screening, withdrawal and Wernicke encephalopathy
Australia measures alcohol in standard drinks, each containing 10 grams of pure alcohol. The NHMRC guideline advises healthy adults to drink no more than 10 standard drinks a week and no more than 4 on any one day to reduce the risk of harm. Children and young people under 18 should not drink, and women who are pregnant, planning pregnancy or breastfeeding are advised not to drink. Screening in general practice commonly uses the AUDIT or the shorter AUDIT-C.
Withdrawal usually starts within 6 to 24 hours of the last drink, with tremor, sweating, anxiety, nausea, tachycardia and insomnia. Seizures can occur, typically in the first two days. Delirium tremens, with confusion, hallucinations and autonomic instability, usually appears around two to three days after stopping and carries a real mortality risk. Use a validated withdrawal scale, such as the Alcohol Withdrawal Scale used in many Australian hospitals or the CIWA-Ar, to guide treatment.
Benzodiazepines are the treatment of choice for alcohol withdrawal. Diazepam is commonly used because its long action smooths the withdrawal course. In severe liver disease, a shorter-acting drug without active metabolites, such as oxazepam, may be preferred, with specialist advice. Treatment is symptom-triggered or given on a set schedule, depending on the setting and the patient.
Thiamine must be given to anyone at risk of Wernicke encephalopathy, and it should be given parenterally before or with glucose in at-risk patients. Wernicke encephalopathy presents with confusion, ataxia and eye signs such as nystagmus or ophthalmoplegia, but many patients have only one or two of these features. Untreated, it can progress to Korsakoff syndrome, with lasting memory impairment and confabulation.
- Standard drink = 10 g alcohol
- NHMRC: no more than 10 a week and 4 on any one day
- Withdrawal scale guides benzodiazepine dosing
- Thiamine before glucose; do not wait for the full triad
- DTs around day two to three are a medical emergency
Alcohol use disorder: relapse prevention
After withdrawal, the aim is to reduce relapse. Psychological treatment such as CBT, motivational interviewing and mutual-help groups form the base. Medicines add benefit and are under-used.
Naltrexone reduces craving and heavy drinking. It is an opioid antagonist, so it cannot be used in people who take opioids, and it would precipitate withdrawal in someone dependent on opioids. Check liver function before and during treatment. Acamprosate helps maintain abstinence and is excreted by the kidneys, so it needs dose adjustment or avoidance in renal impairment. Disulfiram causes an unpleasant reaction with alcohol and is only suitable for motivated patients with supervision.
Liver disease, pancreatitis, cardiomyopathy, cancers and injuries are all linked with alcohol. The exam may ask for the next step in a patient with raised GGT and macrocytosis who denies drinking: a non-judgemental conversation and screening is the answer, not confrontation.
- Naltrexone: not with opioids; check liver function
- Acamprosate: check renal function
- Disulfiram: motivated, supervised patients only
- Combine medicine with psychological support
Opioids: overdose, withdrawal and opioid agonist treatment
Opioid overdose causes reduced consciousness, slow breathing and pinpoint pupils. Treatment is airway and breathing support plus naloxone, given in small repeated doses or by the route available, watching for recurrence of sedation because naloxone is shorter-acting than many opioids. Take-home naloxone is available free and without a prescription in Australia for anyone who may experience or witness an overdose.
Opioid withdrawal is unpleasant but rarely dangerous in otherwise well adults. Features include yawning, rhinorrhoea, lacrimation, dilated pupils, piloerection, abdominal cramps, diarrhoea, muscle aches and anxiety. The Clinical Opiate Withdrawal Scale is used to measure severity.
Opioid agonist treatment is the most effective treatment for opioid dependence. It reduces overdose deaths, crime, blood-borne virus transmission and illicit use. In Australia the options are methadone liquid, sublingual buprenorphine or buprenorphine-naloxone, and long-acting injectable buprenorphine given weekly or monthly.
Buprenorphine is a partial agonist with high receptor affinity. If it is given while a full agonist still occupies the receptors, it displaces the full agonist and causes precipitated withdrawal. The first dose should be given when the patient is in objective, moderate withdrawal. The waiting time is longer after methadone than after short-acting heroin or oxycodone. Buprenorphine has a ceiling effect on respiratory depression, which makes it safer in overdose than methadone.
Methadone is a full agonist with a long and variable half-life. The highest overdose risk is in the first weeks of treatment, so doses are increased slowly. It can prolong the QT interval and interacts with enzyme inducers and inhibitors.
- Overdose: support breathing, give naloxone, observe for re-sedation
- Withdrawal: dilated pupils, yawning, rhinorrhoea, diarrhoea
- Buprenorphine: start in objective moderate withdrawal
- Methadone: slow titration, QT and interaction risks
- Long-acting injectable buprenorphine is available in Australia
Methamphetamine, cannabis, benzodiazepines and gambling
Methamphetamine, particularly crystal methamphetamine ('ice'), causes agitation, paranoia, hallucinations, tachycardia, hypertension and hyperthermia. The priority is safety for the patient and staff, then sedation if needed, usually with a benzodiazepine first, and checking for complications such as hyperthermia, rhabdomyolysis, arrhythmia and stroke. Psychosis often settles with abstinence, but repeated use can cause persistent psychotic illness. Withdrawal brings fatigue, hypersomnia, low mood and strong cravings, and suicide risk can rise in the low phase.
Cannabis can cause anxiety, psychosis in vulnerable people, cognitive effects and dependence. Cannabinoid hyperemesis syndrome causes recurrent bouts of vomiting and abdominal pain in long-term heavy users, often relieved by hot showers; the treatment is to stop cannabis. Medicinal cannabis is prescribed in Australia through TGA pathways, but driving with THC in the system is an offence in most jurisdictions even with a prescription.
Benzodiazepine dependence develops with regular use. Stopping suddenly can cause seizures, so the safe approach is to convert to a long-acting drug such as diazepam and taper slowly over weeks to months. Real-time prescription monitoring is in place across Australia to reduce harm from benzodiazepines, opioids and other monitored medicines.
Gambling disorder is persistent, problematic gambling with loss of control, chasing losses and harm to finances, relationships and work. It is linked with depression, substance use and suicide. Screening, CBT and referral to Gambling Help services are the usual answers.
- Methamphetamine agitation: safety, then benzodiazepine; check temperature and CK
- Cyclical vomiting relieved by hot showers: cannabinoid hyperemesis
- Benzodiazepine taper: switch to diazepam and reduce slowly
- Gambling: screen for depression and suicide risk
Brief intervention and motivational interviewing
Brief intervention is a short, structured conversation in primary care or a hospital setting that reduces risky drinking. The RACGP SNAP guide supports the 5As approach: ask, assess, advise, assist and arrange follow-up. The FRAMES elements are often used too: feedback, responsibility, advice, a menu of options, empathy and self-efficacy.
Motivational interviewing is a collaborative style that helps people resolve ambivalence. It uses open questions, affirmations, reflective listening and summaries. Confronting or lecturing a patient usually increases resistance, so it is a wrong answer in the exam.
The stages of change model is useful for matching the intervention to readiness: precontemplation, contemplation, preparation, action and maintenance, with relapse as a normal part of the cycle. A patient who says 'I know I should cut down but I enjoy it' is in contemplation, and the best next step is to explore the pros and cons with them.
- 5As: ask, assess, advise, assist, arrange
- FRAMES elements for brief intervention
- Motivational interviewing: open questions and reflection
- Match the intervention to the stage of change
Australian practice and how to approach the stems
Several Australian details are examinable. Standard drinks contain 10 grams of alcohol, not 8 grams as in UK units. Opioid agonist treatment is prescribed under state and territory regulations, so prescriber requirements differ between jurisdictions, and many GPs now prescribe buprenorphine in primary care. Take-home naloxone is free. Aboriginal community controlled health services often provide integrated alcohol and drug care, and culturally safe care involves family and community.
In stems, look for the timeline from the last drink or dose, any sign of confusion or eye movement abnormality, and recent drug changes. Ask yourself what could kill the patient today: seizure, delirium tremens, Wernicke encephalopathy, respiratory depression, hyperthermia. Treat that first.
For chronic management stems, the answer is usually the evidence-based treatment that the patient will accept: opioid agonist treatment rather than detoxification alone, a relapse prevention medicine plus support for alcohol, or a slow benzodiazepine taper.
- Inpatient confusion on day two to three: think alcohol withdrawal or Wernicke
- Detoxification alone has high relapse and overdose risk in opioid dependence
- Loss of tolerance after prison release or detox increases overdose risk
- Check for co-occurring mental illness in every substance stem
| Substance | Withdrawal features | Key management point |
|---|---|---|
| Alcohol | Tremor, sweating, anxiety; seizures; delirium tremens | Benzodiazepine by withdrawal scale; parenteral thiamine |
| Opioids | Yawning, rhinorrhoea, mydriasis, diarrhoea, cramps | Opioid agonist treatment; take-home naloxone |
| Methamphetamine | Fatigue, hypersomnia, low mood, craving | Safety first; benzodiazepine for agitation |
| Cannabis | Irritability, poor sleep, reduced appetite | Psychological support; screen for psychosis |
| Benzodiazepines | Anxiety, insomnia, seizures if stopped abruptly | Convert to diazepam; slow taper |
| Nicotine | Irritability, craving, increased appetite | Varenicline or NRT plus behavioural support |
| GHB | Severe, rapid withdrawal with delirium in dependent users | Specialist inpatient management |
Worked examples in AMC style
Pick an answer to see why each option is right or wrong. These examples are written for this page; the bank holds the full set for substance use & addiction.
Example 1
A 52-year-old man is admitted for a fractured ankle. On the second hospital day he becomes tremulous, sweaty and confused, and sees insects on the wall. He has nystagmus and is unsteady when sitting. His partner says he drinks a bottle of wine and several beers each night. Blood glucose is 3.6 mmol/L.
What is the most appropriate immediate step?
-
Giving glucose before thiamine can precipitate or worsen Wernicke encephalopathy.
-
He has features of withdrawal and Wernicke encephalopathy with low glucose. Parenteral thiamine should be given before or with glucose, alongside benzodiazepines for withdrawal.
-
Antipsychotics lower the seizure threshold and do not treat alcohol withdrawal.
-
Imaging may be needed later, but thiamine and glucose must not be delayed.
-
Naltrexone is for relapse prevention after withdrawal, not acute management.
Show answer and reasoning
Answer: B. Give intravenous thiamine then dextrose
- A. Giving glucose before thiamine can precipitate or worsen Wernicke encephalopathy.
- B. He has features of withdrawal and Wernicke encephalopathy with low glucose. Parenteral thiamine should be given before or with glucose, alongside benzodiazepines for withdrawal.
- C. Antipsychotics lower the seizure threshold and do not treat alcohol withdrawal.
- D. Imaging may be needed later, but thiamine and glucose must not be delayed.
- E. Naltrexone is for relapse prevention after withdrawal, not acute management.
At-risk drinker needing glucose: thiamine first or together, never glucose alone.
Based on: Therapeutic Guidelines: Addiction; NSW Health drug and alcohol withdrawal guidelines
Example 2
A 30-year-old woman who uses heroin daily attends a GP clinic and wants to start buprenorphine-naloxone. Her last use of heroin was four hours ago. She is anxious but has normal pupils, no sweating, no yawning and no rhinorrhoea. She has no other medical problems and is not pregnant.
What is the most appropriate next step?
-
Heroin still occupies her receptors. Buprenorphine now would displace it and precipitate withdrawal.
-
Naltrexone would precipitate severe withdrawal in someone dependent on opioids.
-
Prescribing a full agonist for an unsupervised bridge increases overdose and diversion risk.
-
Buprenorphine should start when there are objective signs of moderate withdrawal, which reduces the risk of precipitated withdrawal.
-
Detoxification alone has high relapse and overdose risk; opioid agonist treatment is more effective.
Show answer and reasoning
Answer: D. Wait for objective withdrawal signs
- A. Heroin still occupies her receptors. Buprenorphine now would displace it and precipitate withdrawal.
- B. Naltrexone would precipitate severe withdrawal in someone dependent on opioids.
- C. Prescribing a full agonist for an unsupervised bridge increases overdose and diversion risk.
- D. Buprenorphine should start when there are objective signs of moderate withdrawal, which reduces the risk of precipitated withdrawal.
- E. Detoxification alone has high relapse and overdose risk; opioid agonist treatment is more effective.
Start buprenorphine in objective moderate withdrawal to avoid precipitated withdrawal.
Based on: National Guidelines for Medication-Assisted Treatment of Opioid Dependence; Therapeutic Guidelines: Addiction
Example 3
A 45-year-old man sees his GP for a work medical. He drinks five standard drinks most nights and more at weekends. His AUDIT score suggests hazardous drinking. He says he knows he drinks a bit much but it helps him relax after work. He has no withdrawal symptoms and normal liver function.
What is the most appropriate next step?
-
Confrontation tends to increase resistance and is less effective than a collaborative approach.
-
Medicines are for alcohol use disorder with dependence, not first-line for hazardous drinking.
-
He is ambivalent and drinking above guidelines. A brief intervention with motivational interviewing is effective in primary care.
-
He has no withdrawal symptoms or dependence features that need inpatient care.
-
Normal liver tests and no clinical signs mean imaging is not needed before talking about drinking.
Show answer and reasoning
Answer: C. Use a brief intervention to explore change
- A. Confrontation tends to increase resistance and is less effective than a collaborative approach.
- B. Medicines are for alcohol use disorder with dependence, not first-line for hazardous drinking.
- C. He is ambivalent and drinking above guidelines. A brief intervention with motivational interviewing is effective in primary care.
- D. He has no withdrawal symptoms or dependence features that need inpatient care.
- E. Normal liver tests and no clinical signs mean imaging is not needed before talking about drinking.
Hazardous drinking in primary care: brief intervention with a motivational style.
Based on: RACGP SNAP guide; NHMRC Australian guidelines to reduce health risks from drinking alcohol
Quick recall
Tap a card to turn it over. If you can answer all eight without looking, move on to timed questions.
Where candidates lose marks
- Glucose before thiamine
In at-risk drinkers, give parenteral thiamine before or with glucose.
- Waiting for the full Wernicke triad
Most patients do not have all three features. Treat on suspicion.
- Starting buprenorphine too early
Without objective withdrawal, the first dose can cause precipitated withdrawal.
- Naltrexone in an opioid user
It will cause acute withdrawal and blocks opioid pain relief.
- Stopping benzodiazepines abruptly
Sudden cessation after long-term use can cause seizures. Taper slowly.
How to study substance use & addiction
Step 1: Learn the Australian standard drink and NHMRC limits, and the AUDIT tool.
Step 2: Learn the alcohol withdrawal timeline, withdrawal scales and benzodiazepine treatment.
Step 3: Learn Wernicke and Korsakoff, and the thiamine-before-glucose rule.
Step 4: Study opioid overdose, withdrawal signs and opioid agonist treatment, including buprenorphine induction.
Step 5: Review methamphetamine, cannabis, benzodiazepines and gambling.
Step 6: Practise brief intervention questions and a mixed timed block.
Sources and further reading
Check the current edition of each guideline before your exam. This page is study material, not clinical advice.
- NHMRC Australian guidelines to reduce health risks from drinking alcohol
- Therapeutic Guidelines: Addiction
- Australian Government Department of Health: National Guidelines for Medication-Assisted Treatment of Opioid Dependence
- RACGP: Smoking, nutrition, alcohol, physical activity (SNAP) guide
- Australian Government: Take Home Naloxone program
- Gambling Help Online